Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and billions on the back end—to apply artificial intelligence to up to 20 programs.
Novo Nordisk Stock Rises
Key Takeaways Novo Nordisk shares rose Wednesday on the company's home market in Denmark and in the U.S. after UBS analysts ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” ...
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback